Company / Current Assets
Theravance Biopharma, Inc. Current Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$418.5M
FY2025
5-year range
$133.5M / $418.5M
FY2021-FY2025
Trend
+159.8%
vs FY2024
Sector context
#130 of 213
Health Care
What the data says
At $418M, Theravance Biopharma, Inc.'s current assets ranks #130 of 213 in the Health Care sector. Current Assets has fluctuated over the past 10 years, ranging from $134M in FY2023 to $533M in FY2018.
Based on SEC 10-K filings.
$418M in FY2025 with a 5-year CAGR of +1.2%.
Improved from $134M to $418M over the past 2 years.
Health Care sector context is included.
Current Assets over time
Growth rates
- 3-Year CAGR
- +5.8%
- 5-Year CAGR
- +1.2%
- 10-Year CAGR
- -
Sector benchmark
#130 of 213 in Health CareTop 61% of 213This company $418.5M Sector average $2.5B
▼
-83.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +1.2%, indicating consistent growth.
- In FY2025, current assets increased 159.8% year-over-year.
- Ranks #130 out of 213 companies in the Health Care sector.
- Peak current assets was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $418.5M | +159.8% |
| FY2024 | $161.1M | +20.6% |
| FY2023 | $133.5M | -62.2% |
| FY2022 | $353.5M | +41.5% |
| FY2021 | $249.9M | -36.5% |
| FY2020 | $393.3M | +16.2% |
| FY2019 | $338.5M | -36.5% |
| FY2018 | $532.8M | +40.7% |
| FY2017 | $378.7M | -28.3% |
| FY2016 | $528.5M | +122.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026